Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;86(6):603-606.
doi: 10.1016/j.jinf.2023.02.037. Epub 2023 Mar 1.

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana

Emily Shava  1 , Alane Izu  2 , Tendani Gaolathe  3 , Adam Walker  4 , Lucy Carty  5 , Panayiotis Georgiou  6 , Lesego Kuate  7 , Coulson Kgathi  8 , Tumalano Sekoto  9 , Ngozana Seonyatseng  10 , Tuelo Mogashoa  11 , Comfort Maphorisa  12 , Terence Mohammed  13 , Tshenolo Ntalabgwe  14 , Tshepho T Frank  15 , Boitumelo Matlhaku  16 , Ame Diphoko  17 , Thandie Phindela  18 , Agripa Kaunda  19 , Poloko Kgari  20 , Thomas Kanyakula  21 , Gape Palalani  22 , Isabella Phakedi  23 ; (Botswana AZD1222 study team)  24 ; Sylvia Taylor  25 , Mompati Mmalane  26 , Sikhulile Moyo  27 , Joseph Makhema  28
Affiliations

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana

Emily Shava et al. J Infect. 2023 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest ST and PG are employees of, and hold or may hold stock in, AstraZeneca. AW is an employee of X4 Group contracted to AstraZeneca for this work. LC is an employee of SRG Recruitment contracted to AstraZeneca for this work. All other authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Overall diagram on study population.
See this image and copyright information in PMC

References

    1. Nisar M.I., Ansari N., Malik A.A., Shahid S., Lalani K.R.A., Chandna M.A., et al. Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative case-control study. J Infect. 2023 doi: 10.1016/j.jinf.2023.01.016. S0163-4453(23)00021-X. - DOI - PMC - PubMed
    1. Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993. - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. - PMC - PubMed
    1. Thornton J. Botswana's HIV/AIDS success. Lancet. 2022;400(10351):480–481. - PubMed
    1. Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679–686. - PMC - PubMed

Publication types